Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 12/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 11/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dusquetide SCHEMBL16677021 | 0.86 | NTSR1 (0.45) | NTSR1NTSR2SORT1 | |
| Dusquetide SCHEMBL16671001 | 0.86 | NTSR1 (0.45) | NTSR1NTSR2SORT1 | |
| SCHEMBL29551878 | 0.82 | OPRD1 (0.56) | NTSR1NTSR2SORT1AGTR1NPY1R | |
| SCHEMBL30157099 | 0.77 | XIAP (0.60) | — | |
| SCHEMBL30716931 | 0.76 | NTSR1 (0.55) | NTSR1NTSR2SORT1AGTR1AGTR2 | |
| SCHEMBL29873831 | 0.75 | XIAP (0.51) | NTSR1NTSR2SORT1AGTR1AGTR2 | |
| SCHEMBL29976151 | 0.75 | CALCRL (0.44) | NTSR1NTSR2SORT1 | |
| SCHEMBL28363525 | 0.74 | CAPN1 (0.54) | NTSR1NTSR2 | |
| SCHEMBL30572412 | 0.74 | CAPN1 (0.54) | NTSR1NTSR2 | |
| SCHEMBL29497357 | 0.73 | XIAP (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024104197-A1 | PEPTIDE HYDROGEL, PREPARATION METHOD THEREFOR AND USE THEREOF IN TREATMENT | 中国科学院过程工程研究所 | 2024-05-23 | — | — | WO | disclosed |
| US-20240016882-A1 | AUTOPHAGY-INHIBITING PEPTIDE AND ORGANIC ACID SALT THEREOF ADDRESSING ISSUES OF VASCULAR PERMEABILITY | BIOTEMPT B.V. (NL) | 2024-01-18 | — | — | US | disclosed |
| EP-3044229-B1 | PEPTIDES FOR USE IN THE TREATMENT OF ORAL MUCOSITIS | SOLIGENIX INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIV STRASBOURG (FR) | 2023-06-08 | — | — | US | disclosed |
| CN-116139248-A | Peptide hydrogel, preparation method thereof and application thereof in treatment | 中国科学院过程工程研究所 | 2023-05-23 | — | — | CN | disclosed |
| US-11311598-B2 | Peptides and analogs for use in the treatment of oral mucositis | SOLIGENIX, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022069576-A1 | AUTOPHAGY-INHIBITING PEPTIDE AND ORGANIC ACID SALT THEREOF ADDRESSING ISSUES OF VASCULAR PERMEABILITY | BIOTEMPT B.V. (NL) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311598-B2 | Peptides and analogs for use in the treatment of oral mucositis | IFNAR1, DCLRE1A, VIP | NTSR1 399/4885NTSR2 816/4885SORT1 4644/4885 |
| US-20230173076-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | GPR119, GLP1R, GIPR | NTSR1 35/4885NTSR2 27/4885SORT1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.